Yifeng Pharmacy
Yifeng Pharmacy Chain Co., Ltd. engages in the retail business of pharmaceutical products in China. The company operates through Retail business and Wholesale business segments. It offers Western and Chinese patent medicine, traditional Chinese medicine herbal pieces, medical devices and equipment, health supplements and products, personal care products, drugs, and convenience products related to… Read more
Yifeng Pharmacy (603939) - Total Liabilities
Latest total liabilities as of September 2025: CN¥14.41 Billion CNY
Based on the latest financial reports, Yifeng Pharmacy (603939) has total liabilities worth CN¥14.41 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Yifeng Pharmacy - Total Liabilities Trend (2011–2024)
This chart illustrates how Yifeng Pharmacy's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Yifeng Pharmacy Competitors by Total Liabilities
The table below lists competitors of Yifeng Pharmacy ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Advanced Technology & Materials Co Ltd
SHE:000969
|
China | CN¥5.07 Billion |
|
Meta Financial Group Inc
NASDAQ:CASH
|
USA | $6.71 Billion |
|
Park Hotels & Resorts Inc
NYSE:PK
|
USA | $4.62 Billion |
|
Bandhan Bank Limited
NSE:BANDHANBNK
|
India | ₹1.71 Trillion |
|
Danieli & C RSP
LSE:0N4I
|
UK | €3.44 Billion |
|
Hyundai Autoever Corp
KO:307950
|
Korea | ₩1.48 Trillion |
|
ITC HOTELS LIMITED
NSE:ITCHOTELS
|
India | ₹17.45 Billion |
|
RBL Bank Limited
NSE:RBLBANK
|
India | ₹1.38 Trillion |
Liability Composition Analysis (2011–2024)
This chart breaks down Yifeng Pharmacy's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Yifeng Pharmacy's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Yifeng Pharmacy (2011–2024)
The table below shows the annual total liabilities of Yifeng Pharmacy from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥16.58 Billion | +21.12% |
| 2023-12-31 | CN¥13.69 Billion | +14.87% |
| 2022-12-31 | CN¥11.92 Billion | +29.71% |
| 2021-12-31 | CN¥9.19 Billion | +28.18% |
| 2020-12-31 | CN¥7.17 Billion | +60.49% |
| 2019-12-31 | CN¥4.47 Billion | +20.77% |
| 2018-12-31 | CN¥3.70 Billion | +130.72% |
| 2017-12-31 | CN¥1.60 Billion | +28.65% |
| 2016-12-31 | CN¥1.25 Billion | +22.47% |
| 2015-12-31 | CN¥1.02 Billion | +55.27% |
| 2014-12-31 | CN¥655.19 Million | +24.99% |
| 2013-12-31 | CN¥524.21 Million | +24.92% |
| 2012-12-31 | CN¥419.63 Million | -13.86% |
| 2011-12-31 | CN¥487.12 Million | -- |